NovoCure Quarterly Cash Flow Statement
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
14.58+0.36 (+2.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NovoCure free cash flow
In the quarter ended Jun 30, 2026, NovoCure generated $8.1 million of operating cash flow and spent $6.9 million on capital expenditures. That left free cash flow of $1.2 million, a free-cash-flow margin of 0.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
NovoCure cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -15.66M | -71.14M | -24.50M | -37.27M | -40.14M | -34.32M | -65.92M | -30.57M | -33.38M | -38.76M | -47.08M | -49.48M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.31M | 4.12M | 4.22M | 3.66M | 3.44M | 3.33M | 3.10M | 2.46M | 2.86M | 2.81M | 2.72M | 2.80M |
| Stock-Based Compensation | 17.01M | 63.01M | 19.82M | 29.32M | 26.14M | 29.55M | 62.76M | 31.36M | 31.83M | 34.08M | 17.44M | 26.35M |
| Change in Working Capital | 3.66M | -7.90M | 6.46M | 25.72M | 1.48M | -20.36M | 23.79M | 9.35M | 11.44M | -22.89M | 18.19M | 4.83M |
| Operating Cash Flow | 8.13M | -13.52M | -18.00M | 20.57M | -15.94M | -35.66M | -3.45M | 10.38M | -1.72M | -31.57M | -14.56M | -19.31M |
| Capital Expenditures | -6.92M | -5.15M | -4.90M | -5.66M | -5.49M | -10.61M | -8.94M | -10.68M | -11.45M | -11.78M | -6.82M | -7.25M |
| Investing Cash Flow | -6.38M | 7.75M | 336.33M | 71.44M | 35.99M | -6.47M | -22.21M | 10.19M | -374.44M | 246.22M | 98.50M | 17.26M |
| Debt Issued | 0 | 0 | 0 | 99.98M | 0 | 0 | 0 | 0 | 96.92M | 0 | 0 | 0 |
| Debt Repaid | 0 | 0 | -560.95M | 0 | 0 | 0 | 0 | 0 | -12.91M | 0 | 0 | 0 |
| Financing Cash Flow | 4.55M | -166.00K | -559.49M | 100.52M | 2.39M | 5.25M | 2.69M | 100.00K | 87.32M | 213.00K | 1.91M | 1.17M |
| Net Change in Cash | 6.29M | -6.07M | -241.25M | 192.50M | 22.70M | -36.66M | -23.11M | 20.76M | -288.92M | 214.80M | 86.05M | -982.00K |
| Free Cash Flow | 1.22M | -18.67M | -22.90M | 14.92M | -21.42M | -46.28M | -12.39M | -307.00K | -13.17M | -43.36M | -21.38M | -26.57M |
This table shows 12 quarterly periods of NovoCure's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NVCR's reporting calendar. What is a cash flow statement?